Genscript Biotech (Germany) Today
| G51 Stock | EUR 1.30 0.01 0.76% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Genscript Biotech is trading at 1.30 as of the 5th of February 2025. This is a 0.76% down since the beginning of the trading day. The stock's lowest day price was 1.3. Genscript Biotech has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 6th of January 2025 and ending today, the 5th of February 2025. Click here to learn more.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life sciences research products and services. Genscript Biotech Corporation is a subsidiary of GenScript Corporation. Genscript Biotech operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. The company has 2.12 B outstanding shares. More on Genscript Biotech
Moving together with Genscript Stock
Moving against Genscript Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Genscript Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genscript Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genscript Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Vice President - Strategy | Li Zhu |
| Thematic Idea | IT (View all Themes) |
| Business Concentration | IT, Biotechnology, Healthcare, Computing (View all Sectors) |
Genscript Biotech (G51) is traded on Frankfurt Exchange in Germany and employs 5,573 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.85 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genscript Biotech's market, we take the total number of its shares issued and multiply it by Genscript Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genscript Biotech classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 2.12 B outstanding shares.
Genscript Biotech has accumulated about 564.61 M in cash with (136.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31.
Check Genscript Biotech Probability Of Bankruptcy
Ownership AllocationGenscript Biotech has a total of 2.12 Billion outstanding shares. Genscript Biotech secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genscript Ownership Details
Genscript Biotech Risk Profiles
Although Genscript Biotech's alpha and beta are two of the key measurements used to evaluate Genscript Biotech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.99 | |||
| Standard Deviation | 2.78 | |||
| Variance | 7.71 | |||
| Risk Adjusted Performance | (0.04) |
Genscript Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genscript Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Genscript Biotech Corporate Management
Elected by the shareholders, the Genscript Biotech's board of directors comprises two types of representatives: Genscript Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genscript. The board's role is to monitor Genscript Biotech's management team and ensure that shareholders' interests are well served. Genscript Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genscript Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shiniu Wei | Chief Officer | Profile | |
| Brian Min | CEO Bus | Profile | |
| Zhenyu Liu | Chief Officer | Profile | |
| Weihui Shao | Chief Officer | Profile | |
| Chifa Zhang | Department head - industry synthetic biology product segment | Profile |
Other Information on Investing in Genscript Stock
Genscript Biotech financial ratios help investors to determine whether Genscript Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.